Bivalirudin - Eagle Pharmaceuticals

Drug Profile

Bivalirudin - Eagle Pharmaceuticals

Alternative Names: Bivalirudin RTU; EP-6101; Kangio; Ready-to-use bivalirudin; RTU bivalirudin

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Heparin-induced thrombocytopenia and thrombosis syndrome; Unstable angina pectoris

Most Recent Events

  • 30 Jun 2017 Discontinued - Preregistration for Heparin-induced thrombocytopenia and thrombosis syndrome in USA (IV)
  • 30 Jun 2017 Discontinued - Preregistration for Unstable angina pectoris in USA (IV)
  • 15 Mar 2017 Eagle pharmaceuticals and The Medicines company has patent protection for bivalirudin in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top